You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR Mutation

Showing 1 - 25 of 4,231
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting
  • Aumolertinib
  • +4 more
  • (no location specified)
Mar 8, 2023

NSCLC Trial in Shanghai (IN10018, Furmonertinib)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 8, 2023

EGFR Mutant Advanced NSCLC Trial (BBT-207)

Not yet recruiting
  • EGFR Mutant Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jun 16, 2023

Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

Not yet recruiting
  • Non Squamous Non Small Cell Lung Cancer
  • EGFR Positive Non-small Cell Lung Cancer
  • Toripalimab plus Chemotherapy
  • (no location specified)
Jul 28, 2023

Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

Completed
  • Non-small Cell Lung Cancer
  • (no location specified)
May 8, 2023

Target Therapy for Brain Metastases With EGFR Mutation

Not yet recruiting
  • Brain Metastases
  • Surgery or Radiotherapy
  • before or after target therapy
  • (no location specified)
Nov 8, 2022

Central Nervous System Metastatic EGFR Mutation Positive NSCLC

Not yet recruiting
  • NSCLC
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Aug 6, 2023

    Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 13, 2022

    Real-world Data of Afatinib Treatment in First-line Setting and

    Active, not recruiting
    • Non-squamous, Non-Small Cell Lung Cancer
    • Tokyo, Japan
      Nippon Boehringer Ingelheim Co., Ltd.
    Jan 9, 2023

    EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among

    Recruiting
    • Lung Cancer
    • Kuala Lumpur, Malaysia
    • +2 more
    Nov 21, 2022

    Lung Adenocarcinoma Stage III, EGFR Gene Mutation Trial in Shang'ai (Afatinib)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • EGFR Gene Mutation
    • Shang'ai, Shanghai, China
      Shanghai Pulmonary Hospital
    Mar 27, 2022

    NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 23, 2023

    Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +9 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 25, 2022

    NSCLC Trial in Netherlands (Trastuzumab emtansine, Osimertinib)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • Maastricht, Limburg, Netherlands
    • +4 more
    Nov 7, 2022

    NSCLC Trial (Almonertinib Envafolimab)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Almonertinib Envafolimab
    • (no location specified)
    Sep 10, 2022

    Non Small Cell Lung Cancer Trial in Seoul (Neoadjuvant lazertinib)

    Recruiting
    • Non Small Cell Lung Cancer
    • Neoadjuvant lazertinib
    • Seoul, Korea, Republic of
      Konkuk University Medical Center
    Jul 20, 2022

    NSCLC Trial in Changsha, Shanghai, Hangzhou (H002 capsule)

    Recruiting
    • Non-small Cell Lung Cancer
    • H002 capsule
    • Changsha, Hunan, China
    • +2 more
    Sep 20, 2022

    NSCLC Trial in China (HSK40118)

    Recruiting
    • NSCLC
    • Beijing, Beijing, China
    • +11 more
    Sep 18, 2023

    Nsclc Trial in Lille (procedure, drug, biological)

    Terminated
    • Nsclc
    • Clinical exam
    • +5 more
    • Lille, France
    • +1 more
    Oct 14, 2021

    Lung Adenocarcinoma Stage III Trial in Shanghai (HS-10296 (Almonertinib))

    Recruiting
    • Lung Adenocarcinoma Stage III
    • HS-10296 (Almonertinib)
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Mar 17, 2022

    EGFR Mutation-Related Tumors Trial (NX-019)

    Not yet recruiting
    • EGFR Mutation-Related Tumors
    • (no location specified)
    Aug 22, 2022

    Dalpiciclib Combined With Third-generation EGFR-TKI in EGFR

    Not yet recruiting
    • Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
    • +6 more
      • (no location specified)
      Aug 9, 2022

      NSCLC Trial (QLH11811)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • (no location specified)
      Sep 22, 2022

      NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • +2 more
      • Nintedanib, gefitinib, erlotinib, afatinib
      • (no location specified)
      Oct 2, 2023

      Non-Small Cell Lung Carcinoma Trial in Duarte, Stanford, Nashville (drug, biological, other)

      Terminated
      • Non-Small Cell Lung Carcinoma
      • Duarte, California
      • +2 more
      Apr 6, 2022